[
    {
        "id": 0,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Takeda Pharma A/S. Adcetris (brentuximab vedotin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Adcetris",
        "drug_name_generic": "brentuximab vedotin",
        "first_published": "2012-11-22",
        "last_updated": "2024-03-11",
        "organization": "European Medicines Agency",
        "publication_date": "2023-12-01",
        "url": "https://www.ema.europa.eu/en/documents/product-information/adcetris-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/adcetris"
    },
    {
        "id": 1,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Afinitor (everolimus) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf. Revised June 2022. Accessed March 11, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Afinitor",
        "drug_name_generic": "everolimus",
        "first_published": "2009-09-02",
        "last_updated": "2024-03-11",
        "organization": "European Medicines Agency",
        "publication_date": "2022-06-27",
        "url": "https://www.ema.europa.eu/en/documents/product-information/afinitor-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/afinitor"
    },
    {
        "id": 2,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Janssen-Cilag International N.V. Akeega (abiraterone acetate and niraparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf. Revised June 2023. Accessed March 5, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Akeega",
        "drug_name_generic": "abiraterone acetate and niraparib",
        "first_published": "2023-06-02",
        "last_updated": "2024-03-05",
        "organization": "European Medicines Agency",
        "publication_date": "2023-06-02",
        "url": "https://www.ema.europa.eu/en/documents/product-information/akeega-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/akeega"
    },
    {
        "id": 3,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Alecensa",
        "drug_name_generic": "alectinib",
        "first_published": "2017-04-11",
        "last_updated": "2024-10-18",
        "organization": "European Medicines Agency",
        "publication_date": "2024-06-19",
        "url": "https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/alecensa"
    },
    {
        "id": 4,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Alunbrig (brigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf. Revised September 2023. Accessed March 6, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Alunbrig",
        "drug_name_generic": "brigatinib",
        "first_published": "2018-11-26",
        "last_updated": "2024-03-06",
        "organization": "European Medicines Agency",
        "publication_date": "2023-09-22",
        "url": "https://www.ema.europa.eu/en/documents/product-information/alunbrig-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/alunbrig"
    },
    {
        "id": 5,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Mabxience Research SL. Avastin (bevacizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf. Revised March 2023. Accessed March 11, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Avastin",
        "drug_name_generic": "bevacizumab",
        "first_published": "2009-09-17",
        "last_updated": "2024-03-11",
        "organization": "European Medicines Agency",
        "publication_date": "2023-03-17",
        "url": "https://www.ema.europa.eu/en/documents/product-information/avastin-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/avastin"
    },
    {
        "id": 6,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Blueprint Medicines (Netherlands) B.V. Ayvakyt (avapritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf. Revised February 2024. Accessed March 6, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Ayvakyt",
        "drug_name_generic": "avapritinib",
        "first_published": "2020-09-30",
        "last_updated": "2024-03-06",
        "organization": "European Medicines Agency",
        "publication_date": "2024-02-06",
        "url": "https://www.ema.europa.eu/en/documents/product-information/ayvakyt-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/ayvakyt"
    },
    {
        "id": 7,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pfizer Europe MA EEIG. Besponsa (inotuzumab ozogamicin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf. Revised February 2024. Accessed March 6, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Besponsa",
        "drug_name_generic": "inotuzumab ozogamicin",
        "first_published": "2017-07-13",
        "last_updated": "2024-03-06",
        "organization": "European Medicines Agency",
        "publication_date": "2024-02-14",
        "url": "https://www.ema.europa.eu/en/documents/product-information/besponsa-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/besponsa"
    },
    {
        "id": 8,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Amgen Europe B.V. Blincyto (blinatumomab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf. Revised June 2023. Accessed March 11, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Blincyto",
        "drug_name_generic": "blinatumomab",
        "first_published": "2015-12-07",
        "last_updated": "2024-03-11",
        "organization": "European Medicines Agency",
        "publication_date": "2023-12-06",
        "url": "https://www.ema.europa.eu/en/documents/product-information/blincyto-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/blincyto"
    },
    {
        "id": 9,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pfizer Europe MA EEIG. Bosulif (bosutinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf. Revised May 2023. Accessed March 11, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Bosulif",
        "drug_name_generic": "bosutinib",
        "first_published": "2013-04-09",
        "last_updated": "2024-03-11",
        "organization": "European Medicines Agency",
        "publication_date": "2023-05-17",
        "url": "https://www.ema.europa.eu/en/documents/product-information/bosulif-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif"
    },
    {
        "id": 10,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pierre Fabre Medicament. Braftovi (encorafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Braftovi",
        "drug_name_generic": "encorafenib",
        "first_published": "2018-10-12",
        "last_updated": "2024-10-20",
        "organization": "European Medicines Agency",
        "publication_date": "2024-09-05",
        "url": "https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/braftovi"
    },
    {
        "id": 11,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Sanofi B.V. Caprelsa (vandetanib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf. Revised August 2023. Accessed March 6, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Caprelsa",
        "drug_name_generic": "vandetanib",
        "first_published": "2012-03-02",
        "last_updated": "2024-03-06",
        "organization": "European Medicines Agency",
        "publication_date": "2023-08-16",
        "url": "https://www.ema.europa.eu/en/documents/product-information/caprelsa-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/caprelsa"
    },
    {
        "id": 12,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Cotellic (cobimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf. Revised March 2023. Accessed March 6, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Cotellic",
        "drug_name_generic": "cobimetinib",
        "first_published": "2015-12-10",
        "last_updated": "2024-03-06",
        "organization": "European Medicines Agency",
        "publication_date": "2023-03-06",
        "url": "https://www.ema.europa.eu/en/documents/product-information/cotellic-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/cotellic"
    },
    {
        "id": 13,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Eli Lilly Nederland B.V. Cyramza (ramucirumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf. Revised December 2022. Accessed March 7, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Cyramza",
        "drug_name_generic": "ramucirumab",
        "first_published": "2015-01-21",
        "last_updated": "2024-03-07",
        "organization": "European Medicines Agency",
        "publication_date": "2022-12-13",
        "url": "https://www.ema.europa.eu/en/documents/product-information/cyramza-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/cyramza"
    },
    {
        "id": 14,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Sanofi Winthrop Industrie. Taxotere (docetaxel) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf. Revised December 2023. Accessed March 11, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Taxotere",
        "drug_name_generic": "docetaxel",
        "first_published": "2009-01-13",
        "last_updated": "2024-03-11",
        "organization": "European Medicines Agency",
        "publication_date": "2023-12-14",
        "url": "https://www.ema.europa.eu/en/documents/product-information/taxotere-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/taxotere"
    },
    {
        "id": 15,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Daiichi Sankyo Europe GmbH. Enhertu (trastuzumab deruxtecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf. Revised March 2024. Accessed March 11, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Enhertu",
        "drug_name_generic": "trastuzumab deruxtecan",
        "first_published": "2021-02-08",
        "last_updated": "2024-03-11",
        "organization": "European Medicines Agency",
        "publication_date": "2024-03-05",
        "url": "https://www.ema.europa.eu/en/documents/product-information/enhertu-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/enhertu"
    },
    {
        "id": 16,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Merck Europe B.V. Erbitux (cetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf. Revised May 2022. Accessed March 12, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Erbitux",
        "drug_name_generic": "cetuximab",
        "first_published": "2009-07-14",
        "last_updated": "2024-03-12",
        "organization": "European Medicines Agency",
        "publication_date": "2022-05-25",
        "url": "https://www.ema.europa.eu/en/documents/product-information/erbitux-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/erbitux"
    },
    {
        "id": 17,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "AstraZeneca AB. Faslodex (fulvestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf. Revised August 2022. Accessed March 12, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Faslodex",
        "drug_name_generic": "fulvestrant",
        "first_published": "2009-02-18",
        "last_updated": "2024-03-12",
        "organization": "European Medicines Agency",
        "publication_date": "2022-08-31",
        "url": "https://www.ema.europa.eu/en/documents/product-information/faslodex-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/faslodex"
    },
    {
        "id": 18,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Gavreto (pralsetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Gavreto",
        "drug_name_generic": "pralsetinib",
        "first_published": "2021-12-09",
        "last_updated": "2024-03-07",
        "organization": "European Medicines Agency",
        "publication_date": "2023-11-21",
        "url": "https://www.ema.europa.eu/en/documents/product-information/gavreto-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/gavreto"
    },
    {
        "id": 19,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "AstraZeneca AB. Iressa (gefitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf. Revised July 2023. Accessed March 7, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Iressa",
        "drug_name_generic": "gefitinib",
        "first_published": "2009-07-22",
        "last_updated": "2024-03-07",
        "organization": "European Medicines Agency",
        "publication_date": "2023-07-17",
        "url": "https://www.ema.europa.eu/en/documents/product-information/iressa-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/iressa"
    },
    {
        "id": 20,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Boehringer Ingelheim International GmbH. Giotrif (afatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf. Revised June 2023. Accessed March 7, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Giotrif",
        "drug_name_generic": "afatinib",
        "first_published": "2013-10-16",
        "last_updated": "2024-03-07",
        "organization": "European Medicines Agency",
        "publication_date": "2023-06-21",
        "url": "https://www.ema.europa.eu/en/documents/product-information/giotrif-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/giotrif"
    },
    {
        "id": 21,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Herceptin (trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf. Revised March 2023. Accessed March 12, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Herceptin",
        "drug_name_generic": "trastuzumab",
        "first_published": "2010-03-01",
        "last_updated": "2024-03-12",
        "organization": "European Medicines Agency",
        "publication_date": "2023-03-17",
        "url": "https://www.ema.europa.eu/en/documents/product-information/herceptin-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/herceptin"
    },
    {
        "id": 22,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pfizer Europe MA EEIG. Ibrance (palbociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf. Revised June 2023. Accessed March 13, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Ibrance",
        "drug_name_generic": "palbociclib",
        "first_published": "2016-11-25",
        "last_updated": "2024-03-13",
        "organization": "European Medicines Agency",
        "publication_date": "2023-06-06",
        "url": "https://www.ema.europa.eu/en/documents/product-information/ibrance-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/ibrance"
    },
    {
        "id": 23,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Glivec (imatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf. Revised November 2023. Accessed March 7, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Glivec",
        "drug_name_generic": "imatinib",
        "first_published": "2009-08-18",
        "last_updated": "2024-03-07",
        "organization": "European Medicines Agency",
        "publication_date": "2023-11-20",
        "url": "https://www.ema.europa.eu/en/documents/product-information/glivec-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/glivec"
    },
    {
        "id": 24,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Incyte Biosciences Distribution B.V. Iclusig (ponatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf. Revised October 2022. Accessed March 7, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Iclusig",
        "drug_name_generic": "ponatinib",
        "first_published": "2013-07-11",
        "last_updated": "2024-03-07",
        "organization": "European Medicines Agency",
        "publication_date": "2022-10-21",
        "url": "https://www.ema.europa.eu/en/documents/product-information/iclusig-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/iclusig"
    },
    {
        "id": 25,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "AstraZeneca AB. Imfinzi (durvalumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf. Revised August 2024. Accessed August 24, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Imfinzi",
        "drug_name_generic": "durvalumab",
        "first_published": "2018-10-30",
        "last_updated": "2024-08-24",
        "organization": "European Medicines Agency",
        "publication_date": "2024-08-13",
        "url": "https://www.ema.europa.eu/en/documents/product-information/imfinzi-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi"
    },
    {
        "id": 26,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "AstraZeneca AB. Imjudo (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf. Revised March 2024. Accessed March 13, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Imjudo",
        "drug_name_generic": "tremelimumab",
        "first_published": "2023-03-02",
        "last_updated": "2024-03-13",
        "organization": "European Medicines Agency",
        "publication_date": "2024-03-13",
        "url": "https://www.ema.europa.eu/en/documents/product-information/imjudo-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/imjudo"
    },
    {
        "id": 27,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "GlaxoSmithKline (Ireland) Limited. Jemperli (dostarlimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf. Revised January 2024. Accessed March 9, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Jemperli",
        "drug_name_generic": "dostarlimab",
        "first_published": "2021-05-03",
        "last_updated": "2024-03-09",
        "organization": "European Medicines Agency",
        "publication_date": "2024-01-12",
        "url": "https://www.ema.europa.eu/en/documents/product-information/jemperli-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/jemperli"
    },
    {
        "id": 28,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Merck Sharp & Dohme B.V. Keytruda (pembrolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf. Revised January 2024. Accessed March 10, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Keytruda",
        "drug_name_generic": "pembrolizumab",
        "first_published": "2015-07-30",
        "last_updated": "2024-03-10",
        "organization": "European Medicines Agency",
        "publication_date": "2024-01-11",
        "url": "https://www.ema.europa.eu/en/documents/product-information/keytruda-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda"
    },
    {
        "id": 29,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Kadcyla (trastuzumab emtansine) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf. Revised March 2023. Accessed March 19, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Kadcyla",
        "drug_name_generic": "trastuzumab emtansine",
        "first_published": "2013-12-19",
        "last_updated": "2024-03-19",
        "organization": "European Medicines Agency",
        "publication_date": "2023-03-22",
        "url": "https://www.ema.europa.eu/en/documents/product-information/kadcyla-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/kadcyla"
    },
    {
        "id": 30,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Kisqali (ribociclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Kisqali",
        "drug_name_generic": "ribociclib",
        "first_published": "2017-08-31",
        "last_updated": "2024-03-19",
        "organization": "European Medicines Agency",
        "publication_date": "2023-10-17",
        "url": "https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/kisqali"
    },
    {
        "id": 31,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Mirati Therapeutics B.V. Krazati (adagrasib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Krazati",
        "drug_name_generic": "adagrasib",
        "first_published": "2024-03-13",
        "last_updated": "2024-03-19",
        "organization": "European Medicines Agency",
        "publication_date": "2024-03-13",
        "url": "https://www.ema.europa.eu/en/documents/product-information/krazati-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/krazati"
    },
    {
        "id": 32,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Regeneron Ireland Designated Activity Company (DAC). Libtayo (cemiplimab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Libtayo",
        "drug_name_generic": "cemiplimab",
        "first_published": "2019-07-05",
        "last_updated": "2024-03-19",
        "organization": "European Medicines Agency",
        "publication_date": "2024-01-12",
        "url": "https://www.ema.europa.eu/en/documents/product-information/libtayo-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo"
    },
    {
        "id": 33,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pfizer Europe MA EEIG. Lorviqua (lorlatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf. Revised January 2024. Accessed March 19, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Lorviqua",
        "drug_name_generic": "lorlatinib",
        "first_published": "2019-06-17",
        "last_updated": "2024-03-19",
        "organization": "European Medicines Agency",
        "publication_date": "2024-01-12",
        "url": "https://www.ema.europa.eu/en/documents/product-information/lorviqua-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/lorviqua"
    },
    {
        "id": 34,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Amgen Europe BV. Lumykras (sotorasib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf. Revised February 2024. Accessed March 19, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Lumykras",
        "drug_name_generic": "sotorasib",
        "first_published": "2022-03-31",
        "last_updated": "2024-03-19",
        "organization": "European Medicines Agency",
        "publication_date": "2024-02-27",
        "url": "https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/lumykras"
    },
    {
        "id": 35,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "AstraZeneca AB. Lynparza (olaparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf. Revised August 2024. Accessed August 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Lynparza",
        "drug_name_generic": "olaparib",
        "first_published": "2015-01-09",
        "last_updated": "2024-08-25",
        "organization": "European Medicines Agency",
        "publication_date": "2024-08-20",
        "url": "https://www.ema.europa.eu/en/documents/product-information/lynparza-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza"
    },
    {
        "id": 36,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Taiho Pharma Netherlands B.V. Lytgobi (futibatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf. Revised October 2023. Accessed March 19, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Lytgobi",
        "drug_name_generic": "futibatinib",
        "first_published": "2023-07-18",
        "last_updated": "2024-03-19",
        "organization": "European Medicines Agency",
        "publication_date": "2023-10-19",
        "url": "https://www.ema.europa.eu/en/documents/product-information/lytgobi-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/lytgobi"
    },
    {
        "id": 37,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. MabThera (rituximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf. Revised November 2023. Accessed March 19, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "MabThera",
        "drug_name_generic": "rituximab",
        "first_published": "2009-10-30",
        "last_updated": "2024-03-19",
        "organization": "European Medicines Agency",
        "publication_date": "2023-11-29",
        "url": "https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/mabthera"
    },
    {
        "id": 38,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Mekinist (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf. Revised March 2024. Accessed March 19, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Mekinist",
        "drug_name_generic": "trametinib",
        "first_published": "2014-07-09",
        "last_updated": "2024-03-19",
        "organization": "European Medicines Agency",
        "publication_date": "2024-03-07",
        "url": "https://www.ema.europa.eu/en/documents/product-information/mekinist-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/mekinist"
    },
    {
        "id": 39,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pierre Fabre Medicament. Mektovi (binimetinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Mektovi",
        "drug_name_generic": "binimetinib",
        "first_published": "2018-10-12",
        "last_updated": "2024-10-20",
        "organization": "European Medicines Agency",
        "publication_date": "2024-09-05",
        "url": "https://www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/mektovi"
    },
    {
        "id": 40,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pfizer Europe MA EEIG. Mylotarg (gemtuzumab ozogamicin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf. Revised November 2023. Accessed March 20, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Mylotarg",
        "drug_name_generic": "gemtuzumab ozogamicin",
        "first_published": "2018-05-04",
        "last_updated": "2024-03-20",
        "organization": "European Medicines Agency",
        "publication_date": "2023-11-20",
        "url": "https://www.ema.europa.eu/en/documents/product-information/mylotarg-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/mylotarg"
    },
    {
        "id": 41,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pierre Fabre Medicament. Nerlynx (neratinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf. Revised June 2023. Accessed March 20, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Nerlynx",
        "drug_name_generic": "neratinib",
        "first_published": "2018-09-12",
        "last_updated": "2024-03-20",
        "organization": "European Medicines Agency",
        "publication_date": "2023-06-15",
        "url": "https://www.ema.europa.eu/en/documents/product-information/nerlynx-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/nerlynx"
    },
    {
        "id": 42,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Bristol-Myers Squibb Pharma EEIG. Opdivo (nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Opdivo",
        "drug_name_generic": "nivolumab",
        "first_published": "2015-07-16",
        "last_updated": "2024-03-22",
        "organization": "European Medicines Agency",
        "publication_date": "2024-03-21",
        "url": "https://www.ema.europa.eu/en/documents/product-information/opdivo-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo"
    },
    {
        "id": 43,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Bristol-Myers Squibb Pharma EEIG. Opdualag (relatlimab / nivolumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf. Revised February 2024. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Opdualag",
        "drug_name_generic": "relatlimab / nivolumab",
        "first_published": "2022-09-20",
        "last_updated": "2024-03-22",
        "organization": "European Medicines Agency",
        "publication_date": "2024-02-21",
        "url": "https://www.ema.europa.eu/en/documents/product-information/opdualag-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/opdualag"
    },
    {
        "id": 44,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Stemline Therapeutics B.V. Orserdu (elacestrant) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf. Revised February 2024. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Orserdu",
        "drug_name_generic": "elacestrant",
        "first_published": "2023-11-27",
        "last_updated": "2024-03-22",
        "organization": "European Medicines Agency",
        "publication_date": "2024-02-14",
        "url": "https://www.ema.europa.eu/en/documents/product-information/orserdu-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/orserdu"
    },
    {
        "id": 45,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Incyte Biosciences Distribution B.V. Pemazyre (pemigatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf. Revised September 2023. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Pemazyre",
        "drug_name_generic": "pemigatinib",
        "first_published": "2021-05-04",
        "last_updated": "2024-03-22",
        "organization": "European Medicines Agency",
        "publication_date": "2023-09-12",
        "url": "https://www.ema.europa.eu/en/documents/product-information/pemazyre-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/pemazyre"
    },
    {
        "id": 46,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Perjeta (pertuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf. Revised December 2021. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Perjeta",
        "drug_name_generic": "pertuzumab",
        "first_published": "2013-04-02",
        "last_updated": "2024-05-16",
        "organization": "European Medicines Agency",
        "publication_date": "2024-04-05",
        "url": "https://www.ema.europa.eu/en/documents/product-information/perjeta-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/perjeta"
    },
    {
        "id": 47,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Phesgo (pertuzumab / trastuzumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf. Revised March 2022. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Phesgo",
        "drug_name_generic": "pertuzumab / trastuzumab",
        "first_published": "2021-01-13",
        "last_updated": "2024-03-22",
        "organization": "European Medicines Agency",
        "publication_date": "2022-03-02",
        "url": "https://www.ema.europa.eu/en/documents/product-information/phesgo-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/phesgo"
    },
    {
        "id": 48,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Piqray (alpelisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf. Revised October 2023. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Piqray",
        "drug_name_generic": "alpelisib",
        "first_published": "2020-07-30",
        "last_updated": "2024-03-22",
        "organization": "European Medicines Agency",
        "publication_date": "2023-10-26",
        "url": "https://www.ema.europa.eu/en/documents/product-information/piqray-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/piqray"
    },
    {
        "id": 49,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Eli Lilly Nederland B.V. Retsevmo (selpercatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf. Revised March 2024. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Retsevmo",
        "drug_name_generic": "selpercatinib",
        "first_published": "2021-04-23",
        "last_updated": "2024-06-13",
        "organization": "European Medicines Agency",
        "publication_date": "2024-05-28",
        "url": "https://www.ema.europa.eu/en/documents/product-information/retsevmo-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/retsevmo"
    },
    {
        "id": 50,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Bristol-Myers Squibb Pharma EEIG. Revlimid (lenalidomide) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Revlimid",
        "drug_name_generic": "lenalidomide",
        "first_published": "2009-10-29",
        "last_updated": "2024-03-28",
        "organization": "European Medicines Agency",
        "publication_date": "2024-01-08",
        "url": "https://www.ema.europa.eu/en/documents/product-information/revlimid-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/revlimid"
    },
    {
        "id": 51,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Rozlytrek (entrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Rozlytrek",
        "drug_name_generic": "entrectinib",
        "first_published": "2020-09-11",
        "last_updated": "2024-10-20",
        "organization": "European Medicines Agency",
        "publication_date": "2024-07-03",
        "url": "https://www.ema.europa.eu/en/documents/product-information/rozlytrek-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/rozlytrek"
    },
    {
        "id": 52,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Ltd. Rydapt (midostaurin) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf. Revised July 2023. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Rydapt",
        "drug_name_generic": "midostaurin",
        "first_published": "2017-10-25",
        "last_updated": "2024-03-22",
        "organization": "European Medicines Agency",
        "publication_date": "2023-07-26",
        "url": "https://www.ema.europa.eu/en/documents/product-information/rydapt-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/rydapt"
    },
    {
        "id": 53,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Ltd. Scemblix (asciminib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf. Revised January 2024. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Scemblix",
        "drug_name_generic": "asciminib",
        "first_published": "2022-09-07",
        "last_updated": "2024-03-22",
        "organization": "European Medicines Agency",
        "publication_date": "2024-01-12",
        "url": "https://www.ema.europa.eu/en/documents/product-information/scemblix-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/scemblix"
    },
    {
        "id": 54,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Spexotras (trametinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf. Revised January 2024. Accessed March 28, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Spexotras",
        "drug_name_generic": "trametinib",
        "first_published": "2024-01-17",
        "last_updated": "2024-03-28",
        "organization": "European Medicines Agency",
        "publication_date": "2024-01-17",
        "url": "https://www.ema.europa.eu/en/documents/product-information/spexotras-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/spexotras"
    },
    {
        "id": 55,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Bristol-Myers Squibb Pharma EEIG. Sprycel (dasatinib [anhydrous]) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf. Revised June 2022. Accessed March 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Sprycel",
        "drug_name_generic": "dasatinib",
        "first_published": "2009-08-18",
        "last_updated": "2024-03-22",
        "organization": "European Medicines Agency",
        "publication_date": "2022-06-17",
        "url": "https://www.ema.europa.eu/en/documents/product-information/sprycel-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel"
    },
    {
        "id": 56,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Tabrecta (capmatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf. Revised January 2023. Accessed March 23, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tabrecta",
        "drug_name_generic": "capmatinib",
        "first_published": "2022-09-21",
        "last_updated": "2024-03-23",
        "organization": "European Medicines Agency",
        "publication_date": "2023-01-25",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tabrecta-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tabrecta"
    },
    {
        "id": 57,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Tafinlar (dabrafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tafinlar",
        "drug_name_generic": "dabrafenib",
        "first_published": "2013-09-18",
        "last_updated": "2024-05-20",
        "organization": "European Medicines Agency",
        "publication_date": "2024-03-07",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tafinlar-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tafinlar"
    },
    {
        "id": 58,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "AstraZeneca AB. Tagrisso (osimertinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tagrisso",
        "drug_name_generic": "osimertinib",
        "first_published": "2016-02-17",
        "last_updated": "2024-08-22",
        "organization": "European Medicines Agency",
        "publication_date": "2024-07-23",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tagrisso"
    },
    {
        "id": 59,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pfizer Europe MA EEIG. Talzenna (talazoparib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Talzenna",
        "drug_name_generic": "talazoparib",
        "first_published": "2019-07-08",
        "last_updated": "2024-03-23",
        "organization": "European Medicines Agency",
        "publication_date": "2024-01-16",
        "url": "https://www.ema.europa.eu/en/documents/product-information/talzenna-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/talzenna"
    },
    {
        "id": 60,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Tarceva (erlotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf. Revised May 2023. Accessed March 23, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tarceva",
        "drug_name_generic": "erlotinib",
        "first_published": "2009-07-14",
        "last_updated": "2024-03-23",
        "organization": "European Medicines Agency",
        "publication_date": "2023-05-16",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tarceva-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tarceva"
    },
    {
        "id": 61,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Tasigna (nilotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tasigna",
        "drug_name_generic": "nilotinib",
        "first_published": "2009-09-29",
        "last_updated": "2024-03-23",
        "organization": "European Medicines Agency",
        "publication_date": "2023-11-27",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tasigna-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna"
    },
    {
        "id": 62,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Tecentriq (atezolizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf. Revised March 2024. Accessed March 23, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tecentriq",
        "drug_name_generic": "atezolizumab",
        "first_published": "2017-09-29",
        "last_updated": "2024-03-28",
        "organization": "European Medicines Agency",
        "publication_date": "2024-03-25",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tecentriq-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq"
    },
    {
        "id": 63,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Merck Europe B.V. Tepmetko (tepotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf. Revised November 2023. Accessed March 23, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tepmetko",
        "drug_name_generic": "tepotinib",
        "first_published": "2022-05-05",
        "last_updated": "2024-03-23",
        "organization": "European Medicines Agency",
        "publication_date": "2023-11-20",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tepmetko-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tepmetko"
    },
    {
        "id": 64,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Les Laboratoires Servier. Tibsovo (ivosidenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf. Revised January 2024. Accessed March 23, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tibsovo",
        "drug_name_generic": "ivosidenib",
        "first_published": "2023-05-12",
        "last_updated": "2024-03-23",
        "organization": "European Medicines Agency",
        "publication_date": "2024-01-15",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tibsovo-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tibsovo"
    },
    {
        "id": 65,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "AstraZeneca AB. Tremelimumab AstraZeneca (tremelimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tremelimumab AstraZeneca",
        "drug_name_generic": "tremelimumab",
        "first_published": "2023-04-04",
        "last_updated": "2024-03-25",
        "organization": "European Medicines Agency",
        "publication_date": "2023-09-11",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tremelimumab-astrazeneca-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tremelimumab astrazeneca"
    },
    {
        "id": 66,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Teva B.V. Trisenox (arsenic trioxide) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Trisenox",
        "drug_name_generic": "arsenic trioxide",
        "first_published": "2009-10-08",
        "last_updated": "2024-03-25",
        "organization": "European Medicines Agency",
        "publication_date": "2023-05-25",
        "url": "https://www.ema.europa.eu/en/documents/product-information/trisenox-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/trisenox"
    },
    {
        "id": 67,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Gilead Sciences Ireland UC. Trodelvy (sacituzumab govitecan) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Trodelvy",
        "drug_name_generic": "sacituzumab govitecan",
        "first_published": "2021-11-24",
        "last_updated": "2024-03-25",
        "organization": "European Medicines Agency",
        "publication_date": "2023-08-11",
        "url": "https://www.ema.europa.eu/en/documents/product-information/trodelvy-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/trodelvy"
    },
    {
        "id": 68,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Seagen B.V. Tukysa (tucatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf. Revised August 2023. Accessed March 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tukysa",
        "drug_name_generic": "tucatinib",
        "first_published": "2021-02-18",
        "last_updated": "2024-03-25",
        "organization": "European Medicines Agency",
        "publication_date": "2023-08-21",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tukysa"
    },
    {
        "id": 69,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Tyverb (lapatinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf. Revised May 2023. Accessed March 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tyverb",
        "drug_name_generic": "lapatinib",
        "first_published": "2009-11-17",
        "last_updated": "2024-03-25",
        "organization": "European Medicines Agency",
        "publication_date": "2023-05-10",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tyverb-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb"
    },
    {
        "id": 70,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Amgen Europe B.V. Vectibix (panitumumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf. Revised July 2022. Accessed March 28, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Vectibix",
        "drug_name_generic": "panitumumab",
        "first_published": "2009-06-18",
        "last_updated": "2024-03-28",
        "organization": "European Medicines Agency",
        "publication_date": "2022-07-06",
        "url": "https://www.ema.europa.eu/en/documents/product-information/vectibix-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/vectibix"
    },
    {
        "id": 71,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "AbbVie Deutschland GmbH Co. KG. Venclyxto (venetoclax) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf. Revised October 2022. Accessed March 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Venclyxto",
        "drug_name_generic": "venetoclax",
        "first_published": "2016-12-21",
        "last_updated": "2024-03-25",
        "organization": "European Medicines Agency",
        "publication_date": "2023-10-31",
        "url": "https://www.ema.europa.eu/en/documents/product-information/venclyxto-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/venclyxto"
    },
    {
        "id": 72,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Eli Lilly Nederland B.V. Verzenios (abemaciclib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf. Revised March 2024. Accessed March 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Verzenios",
        "drug_name_generic": "abemaciclib",
        "first_published": "2018-10-29",
        "last_updated": "2024-03-25",
        "organization": "European Medicines Agency",
        "publication_date": "2024-03-12",
        "url": "https://www.ema.europa.eu/en/documents/product-information/verzenios-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/verzenios"
    },
    {
        "id": 73,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Bayer AG. Vitrakvi (larotrectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf. Revised September 2023. Accessed March 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Vitrakvi",
        "drug_name_generic": "larotrectinib",
        "first_published": "2019-10-24",
        "last_updated": "2024-03-25",
        "organization": "European Medicines Agency",
        "publication_date": "2023-09-22",
        "url": "https://www.ema.europa.eu/en/documents/product-information/vitrakvi-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/vitrakvi"
    },
    {
        "id": 74,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pfizer Europe MA EEIG. Vizimpro (dacomitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf. Revised February 2024. Accessed March 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Vizimpro",
        "drug_name_generic": "dacomitinib",
        "first_published": "2019-06-05",
        "last_updated": "2024-03-25",
        "organization": "European Medicines Agency",
        "publication_date": "2024-02-21",
        "url": "https://www.ema.europa.eu/en/documents/product-information/vizimpro-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/vizimpro"
    },
    {
        "id": 75,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pfizer Europe MA EEIG. Xalkori (crizotinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Xalkori",
        "drug_name_generic": "crizotinib",
        "first_published": "2012-11-14",
        "last_updated": "2024-10-20",
        "organization": "European Medicines Agency",
        "publication_date": "2024-09-24",
        "url": "https://www.ema.europa.eu/en/documents/product-information/xalkori-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/xalkori"
    },
    {
        "id": 76,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Astellas Pharma Europe B.V. Xospata (gilteritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf. Revised November 2023. Accessed March 26, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Xospata",
        "drug_name_generic": "gilteritinib",
        "first_published": "2019-11-08",
        "last_updated": "2024-03-26",
        "organization": "European Medicines Agency",
        "publication_date": "2023-11-07",
        "url": "https://www.ema.europa.eu/en/documents/product-information/xospata-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/xospata"
    },
    {
        "id": 77,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Bristol-Myers Squibb Pharma EEIG. Yervoy (ipilimumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf. Revised March 2024. Accessed March 26, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Yervoy",
        "drug_name_generic": "ipilimumab",
        "first_published": "2011-07-25",
        "last_updated": "2024-03-28",
        "organization": "European Medicines Agency",
        "publication_date": "2024-03-21",
        "url": "https://www.ema.europa.eu/en/documents/product-information/yervoy-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/yervoy"
    },
    {
        "id": 78,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Roche Registration GmbH. Zelboraf (vemurafenib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf. Revised July 2023. Accessed March 26, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Zelboraf",
        "drug_name_generic": "vemurafenib",
        "first_published": "2012-03-19",
        "last_updated": "2024-03-26",
        "organization": "European Medicines Agency",
        "publication_date": "2023-07-18",
        "url": "https://www.ema.europa.eu/en/documents/product-information/zelboraf-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/zelboraf"
    },
    {
        "id": 79,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Gilead Sciences Ireland UC. Zydelig (idelalisib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf. Revised June 2023. Accessed March 26, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Zydelig",
        "drug_name_generic": "idelalisib",
        "first_published": "2014-10-14",
        "last_updated": "2024-03-26",
        "organization": "European Medicines Agency",
        "publication_date": "2023-06-23",
        "url": "https://www.ema.europa.eu/en/documents/product-information/zydelig-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/zydelig"
    },
    {
        "id": 80,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Novartis Europharm Limited. Zykadia (ceritinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf. Revised December 2023. Accessed March 26, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Zykadia",
        "drug_name_generic": "ceritinib",
        "first_published": "2015-06-04",
        "last_updated": "2024-03-26",
        "organization": "European Medicines Agency",
        "publication_date": "2023-12-07",
        "url": "https://www.ema.europa.eu/en/documents/product-information/zykadia-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/zykadia"
    },
    {
        "id": 81,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "BeiGene Ireland Ltd. Tevimbra (tislelizumab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf. Revised July 2024. Accessed August 22, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Tevimbra",
        "drug_name_generic": "tislelizumab",
        "first_published": "2023-10-02",
        "last_updated": "2024-08-22",
        "organization": "European Medicines Agency",
        "publication_date": "2024-07-25",
        "url": "https://www.ema.europa.eu/en/documents/product-information/tevimbra-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/tevimbra"
    },
    {
        "id": 82,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Janssen-Cilag International N.V. Rybrevant (amivantamab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf. Revised July 2024. Accessed August 25, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Rybrevant",
        "drug_name_generic": "amivantamab",
        "first_published": "2022-02-01",
        "last_updated": "2024-08-25",
        "organization": "European Medicines Agency",
        "publication_date": "2024-07-11",
        "url": "https://www.ema.europa.eu/en/documents/product-information/rybrevant-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/rybrevant"
    },
    {
        "id": 83,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "AstraZeneca AB. Truqap (capivasertib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf. Revised July 2024. Accessed October 18, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Truqap",
        "drug_name_generic": "capivasertib",
        "first_published": "2024-07-11",
        "last_updated": "2024-10-18",
        "organization": "European Medicines Agency",
        "publication_date": "2024-07-11",
        "url": "https://www.ema.europa.eu/en/documents/product-information/truqap-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/truqap"
    },
    {
        "id": 84,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Janssen-Cilag International N.V. Balversa (erdafitinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf. Revised August 2024. Accessed October 19, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Balversa",
        "drug_name_generic": "erdafitinib",
        "first_published": "2024-08-29",
        "last_updated": "2024-10-19",
        "organization": "European Medicines Agency",
        "publication_date": "2024-08-29",
        "url": "https://www.ema.europa.eu/en/documents/product-information/balversa-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/balversa"
    },
    {
        "id": 85,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Astellas Pharma Europe B.V. Vyloy (zolbetuximab) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf. Revised September 2024. Accessed October 20, 2024.",
        "document_type": "Government agency",
        "drug_name_brand": "Vyloy",
        "drug_name_generic": "zolbetuximab",
        "first_published": "2024-09-23",
        "last_updated": "2024-10-20",
        "organization": "European Medicines Agency",
        "publication_date": "2024-09-23",
        "url": "https://www.ema.europa.eu/en/documents/product-information/vyloy-epar-product-information_en.pdf",
        "url_epar": "https://www.ema.europa.eu/en/medicines/human/EPAR/vyloy"
    },
    {
        "id": 86,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Afatinib Therapy, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 16/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/221.pdf",
        "document_type": "Government agency",
        "last_updated": "2023-12-16",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-02-26",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/221.pdf"
    },
    {
        "id": 87,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Alectinib Monotherapy, 2021, version number 5, NCCP National SACT Regimen, NCCP, viewed 16/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/401.pdf",
        "document_type": "Government agency",
        "last_updated": "2023-12-16",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-01-06",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/401.pdf"
    },
    {
        "id": 88,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Asciminib Monotherapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 16/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/847-asciminib-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2023-12-16",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/847-asciminib-therapy.pdf"
    },
    {
        "id": 89,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Bosutinib Monotherapy, 2021, version number 4, NCCP National SACT Regimen, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/224-bosutinib-monotherapy-regimen.pdf",
        "document_type": "Government agency",
        "last_updated": "2023-12-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-03-22",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/224-bosutinib-monotherapy-regimen.pdf"
    },
    {
        "id": 90,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Brigatinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/562-brigatinib-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2023-12-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-10-22",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/562-brigatinib-therapy.pdf"
    },
    {
        "id": 91,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Ceritinib Monotherapy, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/340-ceritinib-monotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2023-12-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-11-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/340-ceritinib-monotherapy.pdf"
    },
    {
        "id": 92,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Cobimetinib and Vemurafenib Therapy, 2020, version number 2, NCCP National SACT Regimen, NCCP, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/cobimetinib%20and%20vemurafenib%20therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2023-12-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-05-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/cobimetinib%20and%20vemurafenib%20therapy.pdf"
    },
    {
        "id": 93,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Crizotinib Monotherapy, 2020, version number 6, NCCP National SACT Regimen, NCCP, viewed 19/12/2023, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdf",
        "document_type": "Government agency",
        "last_updated": "2023-12-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-01-08",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/243-crizotinib-monotherapy-regimen.pdf"
    },
    {
        "id": 94,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Dabrafenib Monotherapy, 2021, version number 5, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/237dabrafenib.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-08",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-06-23",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/237dabrafenib.pdf"
    },
    {
        "id": 95,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Dacomitinib Monotherapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/565-dacomitinib-monotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-08",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-06-23",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/565-dacomitinib-monotherapy.pdf"
    },
    {
        "id": 96,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Encorafenib and Binimetinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-08",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-06-23",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/563-envorafenib-and-binimetinib-therapy.pdf"
    },
    {
        "id": 97,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Entrectinib Therapy, 2022, version number 1, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-08",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-05-25",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf"
    },
    {
        "id": 98,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Lorlatinib Therapy, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570%20lorlatinib%20therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-08",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-09-29",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/570%20lorlatinib%20therapy.pdf"
    },
    {
        "id": 99,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Midostaurin, DAUNOrubicin and Cytarabine Induction Therapy, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 08/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/682.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-08",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-12-08",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/682.pdf"
    },
    {
        "id": 100,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Neratinib Therapy, 2022, version number 1, NCCP National SACT Regimen, NCCP, viewed 11/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-11",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-02-09",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/720.pdf"
    },
    {
        "id": 101,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Niraparib and Abiraterone acetate (Akeega) and prednisoLONE Therapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/848-niraparib-and-abiraterone-acetate-akeega-and-prednisolone-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/848-niraparib-and-abiraterone-acetate-akeega-and-prednisolone-therapy.pdf"
    },
    {
        "id": 102,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Olaparib (Tablet) and Bevacizumab Therapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-09-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/746-olaparib-tablet-and-bevacizumab-therapy.pdf"
    },
    {
        "id": 103,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Olaparib (Tablet) Monotherapy, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-03-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/588-olaparib-tablet-monotherapy.pdf"
    },
    {
        "id": 104,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Osimertinib Monotherapy, 2024, version number 5, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-03-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/353-osimertinib-monotherapy.pdf"
    },
    {
        "id": 105,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "PONATinib Therapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/ponatinib-therapy-302.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-06-21",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/medonc/cdmp/ponatinib-therapy-302.pdf"
    },
    {
        "id": 106,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Talazoparib Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/605-talazoparib-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-09-06",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/605-talazoparib-therapy.pdf"
    },
    {
        "id": 107,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Trametinib and Dabrafenib Therapy, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed on 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-11-11",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/dabrafenib%20and%20trametinib%20therapy.pdf"
    },
    {
        "id": 108,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Vemurafenib Monotherapy, 2020, version number 5, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/102-vemurafenib-monotherapy-regimen.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-01-08",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/melanoma/102-vemurafenib-monotherapy-regimen.pdf"
    },
    {
        "id": 109,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Venetoclax Monotherapy 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-03-03",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/400.pdf"
    },
    {
        "id": 110,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Zanubrutinib Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/708-zanubrutinib-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-09-12",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/708-zanubrutinib-therapy.pdf"
    },
    {
        "id": 111,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Acalabrutinib (Tablets) Monotherapy, 2023, version number 1a, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/840-acalabrutinib-tablets-monotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-12-13",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/840-acalabrutinib-tablets-monotherapy.pdf"
    },
    {
        "id": 112,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Ibrutinib Therapy CLL / Waldenstroms Macroglobulinaemia, 2022, version number 5, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-11-28",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/296.pdf"
    },
    {
        "id": 113,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Idelalisib and riTUXimab Therapy, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2019-02-11",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/idelalisib-and-rituximab-v2-389.pdf"
    },
    {
        "id": 114,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Nivolumab 3mg/kg with Ipilimumab 1mg/kg Therapy, 2023, version number 6, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/551-nivolumab-3mg-ipilimumab-1mg-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-06-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/genitourinary/551-nivolumab-3mg-ipilimumab-1mg-therapy.pdf"
    },
    {
        "id": 115,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab 200mg Monotherapy, 2023, version number 13, NCCP National SACT Regimen, NCCP, viewed 18/01/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-01-18",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-04-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-200mg-monotherapy-455.pdf"
    },
    {
        "id": 116,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Larotrectinib Monotherapy - Paediatric, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 01/02/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/760%20larotrectinib-monotherapy-paediatric.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-02-13",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-04-28",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/760%20larotrectinib-monotherapy-paediatric.pdf"
    },
    {
        "id": 117,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Larotrectinib Monotherapy - Adult, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 01/02/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/758-larotrectinib-monotherapy-adult.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-02-13",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-04-28",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/tumour%20agnostic%20therapy/758-larotrectinib-monotherapy-adult.pdf"
    },
    {
        "id": 118,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Gefitinib Monotherapy, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 22/02/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/220-gefitinib-monotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-02-22",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-04-29",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/220-gefitinib-monotherapy.pdf"
    },
    {
        "id": 119,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Erlotinib Therapy, 2021, version number 5, NCCP National SACT Regimen, NCCP, viewed 22/02/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-02-22",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-03-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/219.pdf"
    },
    {
        "id": 120,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Trastuzumab Emtansine (Kadcyla) - 21 days, 2017, version number 2, NCCP National SACT Regimen, NCCP, viewed 01/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/trastuzumab-emtansine-kadcyla%C2%AE-21-days.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-01",
        "organization": "National Cancer Control Programme",
        "publication_date": "2017-09-20",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/trastuzumab-emtansine-kadcyla%C2%AE-21-days.pdf"
    },
    {
        "id": 121,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Palbociclib Therapy - 28 day, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 01/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-01",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-10-23",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/414-palbociclib-therapy-28-days.pdf"
    },
    {
        "id": 122,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Ribociclib Therapy - 28 day, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 03/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-03",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-08-19",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/525-ribociclib-therapy-28-day.pdf"
    },
    {
        "id": 123,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Inotuzumab Ozogamicin Monotherapy, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 03/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/537-inotuzumab-ozogamicin-monotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-03",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-11-19",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/537-inotuzumab-ozogamicin-monotherapy.pdf"
    },
    {
        "id": 124,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Blinatumomab Paediatric Therapy, 2019, version number 1, NCCP National SACT Regimen, NCCP, viewed 03/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/p567-blinatumomab-paediatric-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-03",
        "organization": "National Cancer Control Programme",
        "publication_date": "2019-07-16",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/p567-blinatumomab-paediatric-therapy.pdf"
    },
    {
        "id": 125,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Brentuximab vedotin, Etoposide, methylPREDNISolone, Cytarabine and CISplatin, (ESHAP) therapy (BRESHAP), 2019, version number 2, NCCP National SACT Regimen, NCCP, viewed 16/10/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/530.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-10-16",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-08-24",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/530.pdf"
    },
    {
        "id": 126,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab and Trastuzumab and Chemotherapy Therapy - 21 day cycle, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-09-01",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/350%20pertuzumab%20and%20trastuzumab%20and%20chemotherapy.pdf"
    },
    {
        "id": 127,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Gemtuzumab ozogamicin DAUNOrubicin and cytarabine Therapy (AML induction), 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/612-gemtuzumab-ozogamicin-therpay.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-07-29",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/612-gemtuzumab-ozogamicin-therpay.pdf"
    },
    {
        "id": 128,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab, PEMEtrexed and CARBOplatin (AUC 5) Therapy, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/568.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-07-04",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/568.pdf"
    },
    {
        "id": 129,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab, PEMEtrexed and CISplatin Therapy, 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/569.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-12-19",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/569.pdf"
    },
    {
        "id": 130,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Durvalumab Monotherapy 10mg/kg - 14 Day, 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/576.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-09-04",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/576.pdf"
    },
    {
        "id": 131,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Atezolizumab Monotherapy, 2024, version number 13, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-09-01",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-06-14",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/544-atezolizumab-1200mg-monotherapy.pdf"
    },
    {
        "id": 132,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Trastuzumab Emtansine (Kadcyla) Early Breast Cancer Therapy - 21 days, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/659-trastuzumab-emtansine-kadcyla-early-breast-cancer-therapy-21-days.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-02-23",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/659-trastuzumab-emtansine-kadcyla-early-breast-cancer-therapy-21-days.pdf"
    },
    {
        "id": 133,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab, CARBOplatin (AUC 5) and 5-Fluorouracil Therapy, 2023, version number 2a, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/705-pembrolizumab-carboplatin-and-5-fu-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-21",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/705-pembrolizumab-carboplatin-and-5-fu-therapy.pdf"
    },
    {
        "id": 134,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab, Cisplatin and 5-Fluorouracil Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/706-pembrolizumab-cisplatin-and-5-fu-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-04-26",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/706-pembrolizumab-cisplatin-and-5-fu-therapy.pdf"
    },
    {
        "id": 135,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Nivolumab, ipilimumab, CARBOplatin and PACLitaxel Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/712.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-12-14",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/712.pdf"
    },
    {
        "id": 136,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Nivolumab, ipilimumab, PEMEtrexed and CARBOplatin Therapy, 2022, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/713.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-01-25",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/713.pdf"
    },
    {
        "id": 137,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Nivolumab, ipilimumab, PEMEtrexed and CISplatin Therapy, 2022, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/714.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-01-25",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/714.pdf"
    },
    {
        "id": 138,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Atezolizumab and nab-PACLitaxel Therapy, 2022, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/688.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-12-16",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/688.pdf"
    },
    {
        "id": 139,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Blinatumomab Therapy (ALL with MRD >= 0.1%), 2022, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/590-blinatumomab-mrd.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-10-04",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/590-blinatumomab-mrd.pdf"
    },
    {
        "id": 140,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Blinatumomab for Relapsed Paediatric ALL: Consolidation Therapy, 2022, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/707-blinatumomab-rall-consolidation-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-05-06",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/paediatric/707-blinatumomab-rall-consolidation-therapy.pdf"
    },
    {
        "id": 141,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab and Trastuzumab (Phesgo), PACLitaxel and CARBOplatin Therapy (TRAIN-2), 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/790-pertuzumab-trastuzumab-phesgo-paclitaxel-and-carboplatin-therapy-train-2-.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/790-pertuzumab-trastuzumab-phesgo-paclitaxel-and-carboplatin-therapy-train-2-.pdf"
    },
    {
        "id": 142,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Brentuximab vedotin Monotherapy, 2022, version number 5, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-12-20",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/234-brentuximab-vedotin-monotherapy-regimen.pdf"
    },
    {
        "id": 143,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Brentuximab vedotin and ICE Therapy, 2020, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/528.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-11-12",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/528.pdf"
    },
    {
        "id": 144,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab 200mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy, 2024, version number 1c, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/739-pembrolizumab-200mg-cisplatin-80mg-m2-and-5-fluorouracil-infusional-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-01-26",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/739-pembrolizumab-200mg-cisplatin-80mg-m2-and-5-fluorouracil-infusional-therapy.pdf"
    },
    {
        "id": 145,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Nivolumab 480mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/832-nivolumab-cisplatin.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-01-08",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/832-nivolumab-cisplatin.pdf"
    },
    {
        "id": 146,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Atezolizumab 1680mg Monotherapy - 28 Day, 2024, version number 10a, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-04",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-03-26",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/593-atezolizumab-1680mg-monotherapy-28-day.pdf"
    },
    {
        "id": 147,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab and FOLFOX-6 Modified Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/839-pembrolizumab-and-folfox-6-modified-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-15",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-01-26",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/839-pembrolizumab-and-folfox-6-modified-therapy.pdf"
    },
    {
        "id": 148,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Blinatumomab Therapy, 2022, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/538-blinatumomab-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-15",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-10-04",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/538-blinatumomab-therapy.pdf"
    },
    {
        "id": 149,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab/Trastuzumab (Phesgo) and Weekly PACLitaxel Therapy - 21 day cycle, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/797-pertuzumab-trastuzumab-phesgo-and-weekly-paclitaxel-therapy-21-day-cycle.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-15",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/797-pertuzumab-trastuzumab-phesgo-and-weekly-paclitaxel-therapy-21-day-cycle.pdf"
    },
    {
        "id": 150,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab,Trastuzumab and Weekly PACLitaxel Therapy - 21 day cycle, 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/507.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-15",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/507.pdf"
    },
    {
        "id": 151,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab/Trastuzumab (Phesgo) and DOCEtaxel Therapy - 21 day cycle, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/796-pertuzumab-and-trastuzumab-phesgo-and-docetaxel-therapy-21-day-cycle.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-15",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/796-pertuzumab-and-trastuzumab-phesgo-and-docetaxel-therapy-21-day-cycle.pdf"
    },
    {
        "id": 152,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab,Trastuzumab and DOCEtaxel Therapy - 21 day cycle, 2023, version number 10, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/204-pertuzumab-and-trastuzumab-and-docetaxel-therapy-21-day-cycle.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-15",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/204-pertuzumab-and-trastuzumab-and-docetaxel-therapy-21-day-cycle.pdf"
    },
    {
        "id": 153,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab/Trastuzumab (Phesgo) and Vinorelbine, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/798-pertuzumab-trastuzumab-phesgo-and-vinorelbine-i-.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-15",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/798-pertuzumab-trastuzumab-phesgo-and-vinorelbine-i-.pdf"
    },
    {
        "id": 154,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab, Trastuzumab, and Vinorelbine, 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/526-pertuzumab-trastuzumab-and-vinorelbine.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-15",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/526-pertuzumab-trastuzumab-and-vinorelbine.pdf"
    },
    {
        "id": 155,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab/Trastuzumab (Phesgo) Maintenance Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/785-pertuzumab-and-trastuzumab-phesgo-maintenance-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-15",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/785-pertuzumab-and-trastuzumab-phesgo-maintenance-therapy.pdf"
    },
    {
        "id": 156,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "DOCEtaxel, CARBOplatin, Trastuzumab and Pertuzumab (TCHP) Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 15/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/722-docetaxel-carboplatin-trastuzumab-and-pertuzumab-tchp-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-04-15",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/722-docetaxel-carboplatin-trastuzumab-and-pertuzumab-tchp-therapy.pdf"
    },
    {
        "id": 157,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Nivolumab 360mg and Chemotherapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 19/06/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/849-nivolumab-360mg-and-chemotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-06-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-04-27",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/849-nivolumab-360mg-and-chemotherapy.pdf"
    },
    {
        "id": 158,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab 200mg, weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 19/06/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/858-pembrolizumab-200mg-weekly-carboplatin-auc-1-5-and-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-06-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-06-04",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/858-pembrolizumab-200mg-weekly-carboplatin-auc-1-5-and-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf"
    },
    {
        "id": 159,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Trastuzumab (IV) Monotherapy - 21 days, 2022, version number 7, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-04-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/200-trastuzumab-iv-monotherapy-21.pdf"
    },
    {
        "id": 160,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Trastuzumab (IV) Monotherapy - 7 days, 2022, version number 5, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/201.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-04-21",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/201.pdf"
    },
    {
        "id": 161,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Bevacizumab 10mg/kg - 14 days, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/212.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-04-28",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/212.pdf"
    },
    {
        "id": 162,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Bevacizumab 15mg/kg Therapy - 21 days, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/215.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-04-28",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/215.pdf"
    },
    {
        "id": 163,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Capecitabine Monotherapy, 2023, version number 7, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/216.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-01-18",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/216.pdf"
    },
    {
        "id": 164,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Lapatinib and Capecitabine Therapy, 2021, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/217.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-02-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/217.pdf"
    },
    {
        "id": 165,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Tamoxifen Monotherapy, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-11-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/253tamoxifen.pdf"
    },
    {
        "id": 166,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Anastrozole Monotherapy, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-11-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/254.pdf"
    },
    {
        "id": 167,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days, 2023, version number 8, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/258.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-09-04",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/258.pdf"
    },
    {
        "id": 168,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Trastuzumab Subcutaneous 21 days - Metastatic Breast Cancer, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-09-09",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/272.pdf"
    },
    {
        "id": 169,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Trastuzumab Subcutaneous 21 days - Early Breast Cancer, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-09-09",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/285.pdf"
    },
    {
        "id": 170,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Everolimus and Exemestane Therapy, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/322-everolimus-and-exemestane-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-05-13",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/322-everolimus-and-exemestane-therapy.pdf"
    },
    {
        "id": 171,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "CARBOplatin (AUC 6) and Weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy-Triple Negative Breast Cancer Therapy, 2022, version number 7, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/348.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-10-16",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-09-30",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/348.pdf"
    },
    {
        "id": 172,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Fulvestrant Therapy, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/361.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-12-09",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/361.pdf"
    },
    {
        "id": 173,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Letrozole Monotherapy, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-12-09",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf"
    },
    {
        "id": 174,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Exemestane Monotherapy, 2021, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-01-06",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/376.pdf"
    },
    {
        "id": 175,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Gemcitabine and CARBOplatin (AUC2) Therapy - 21 days, 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/430-gemcitabine-and-carboplatin-auc2-therapy-21-days.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-09-22",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/430-gemcitabine-and-carboplatin-auc2-therapy-21-days.pdf"
    },
    {
        "id": 176,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "DOXOrubicin, cycloPHOSphamide (AC 60/600) 21 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (AC-TH), 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/432-doxorubicin-cyclophosphamide-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-ac-th-.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-04-17",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/432-doxorubicin-cyclophosphamide-followed-by-weekly-paclitaxel-80-and-weekly-trastuzumab-therapy-ac-th-.pdf"
    },
    {
        "id": 177,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "PACLitaxel (80) and Trastuzumab Therapy - 7 day (12 weeks), 2022, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/512-paclitaxel-80-and-trastuzumab-therapy-%E2%80%93-7-day-12-weeks-.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-11-29",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/512-paclitaxel-80-and-trastuzumab-therapy-%E2%80%93-7-day-12-weeks-.pdf"
    },
    {
        "id": 178,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Abemaciclib Therapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-05-31",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/619-abemaciclib-therapy.pdf"
    },
    {
        "id": 179,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab and Trastuzumab Therapy, 2024, version number 3a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/726-pertuzumab-trastuzumab-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-05-29",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/726-pertuzumab-trastuzumab-therapy.pdf"
    },
    {
        "id": 180,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "DOCEtaxel, CARBOplatin, Trastuzumab (S/C) and Pertuzumab (TCH(S/C)P) Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/731-docetaxel-carboplatin-trastuzumab-s-c-and-pertuzumab-tch-s-c-p-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/731-docetaxel-carboplatin-trastuzumab-s-c-and-pertuzumab-tch-s-c-p-therapy.pdf"
    },
    {
        "id": 181,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "CARBOplatin (AUC 2) weekly and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin cycloPHOSphamide Therapy - Triple Negative Breast Cancer Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/734-carboplatin-auc-2-and-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-cyclophosphamide-therapy-triple-negative-breast-cancer-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-05-27",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/734-carboplatin-auc-2-and-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-cyclophosphamide-therapy-triple-negative-breast-cancer-therapy.pdf"
    },
    {
        "id": 182,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pertuzumab, Trastuzumab, PACLitaxel and CARBOplatin Therapy (TRAIN-2), 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/775-pertuzumab-trastuzumab-paclitaxel-and-carboplatin-therapy-train-2-.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-08-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/775-pertuzumab-trastuzumab-paclitaxel-and-carboplatin-therapy-train-2-.pdf"
    },
    {
        "id": 183,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "DOCEtaxel, CARBOplatin and Pertuzumab/Trastuzumab (Phesgo)(TCHP) Therapy, 2024, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/789-docetaxel-carboplatin-and-pertuzumab-trastuzumab-phesgo-tchp-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-06-07",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/789-docetaxel-carboplatin-and-pertuzumab-trastuzumab-phesgo-tchp-therapy.pdf"
    },
    {
        "id": 184,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab 200mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m 2 followed by DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/857-pembrolizumab-200mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-06-04",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/857-pembrolizumab-200mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-doxorubicin-and-cyclophosphamide.pdf"
    },
    {
        "id": 185,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Dose Dense DOXOrubicin, cycloPHOSphamide (AC 60/600) 14 day followed by weekly PACLitaxel (80) and weekly Trastuzumab Therapy (DD AC-TH), 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/dose-dense-acth-433.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-10-18",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/dose-dense-acth-433.pdf"
    },
    {
        "id": 186,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Cetuximab Therapy-7 day, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/207.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-02-12",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/207.pdf"
    },
    {
        "id": 187,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Panitumumab 6mg/kg Therapy, 2020, version number 5, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/225.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-11-10",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/225.pdf"
    },
    {
        "id": 188,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Cetuximab (7 days) and FOLFIRI (14 days) Therapy, 2023, version number 6a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/328.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-23",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/328.pdf"
    },
    {
        "id": 189,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Cetuximab (7 days) and Irinotecan (14 days) Therapy, 2022, version number 5, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/330-cetuximab-7days-and-irinotecan-14-days-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-01-17",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/330-cetuximab-7days-and-irinotecan-14-days-therapy.pdf"
    },
    {
        "id": 190,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Cetuximab (14 days) and Irinotecan (14 days) Therapy, 2022, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/331-cetuximab-14-days-and-irinotecan-14-days-therapy-.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-01-17",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/331-cetuximab-14-days-and-irinotecan-14-days-therapy-.pdf"
    },
    {
        "id": 191,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Panitumumab 6mg/kg and Modified FOLFOX-6 Therapy - 14 day, 2023, version number 6a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/447.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-21",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/447.pdf"
    },
    {
        "id": 192,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Panitumumab 6mg/kg and FOLFIRI Therapy-14 day, 2023, version number 4a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/448%20panitumumab-6mg-kg-and-folfiri-therapy-14-day.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-21",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/448%20panitumumab-6mg-kg-and-folfiri-therapy-14-day.pdf"
    },
    {
        "id": 193,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Trastuzumab 5-Fluorouracil and CISplatin Therapy - 21 days, 2023, version number 3a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/502trastuzumab-5-fluorouracil-and-cisplatin-therapy-21.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-21",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/502trastuzumab-5-fluorouracil-and-cisplatin-therapy-21.pdf"
    },
    {
        "id": 194,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Cetuximab (14 days) and FOLFIRI (14 days) Therapy, 2023, version number 5a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/585.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-21",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/585.pdf"
    },
    {
        "id": 195,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Nivolumab 240mg, CISplatin 80mg/m2 and 5-Fluorouracil Infusional Therapy, 2023, version number 1a, NCCP National SACT Regimen, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/816-nivolumab-cisplatin.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-21",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/816-nivolumab-cisplatin.pdf"
    },
    {
        "id": 196,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Nivolumab and FOLFOX-6 Modified Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/844-nivolumab-and-folfox-6-modified-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-02-20",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/844-nivolumab-and-folfox-6-modified-therapy.pdf"
    },
    {
        "id": 197,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab 400mg Monotherapy, 2023, version number 10, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-400mg-monotherapy-558.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-04-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gastrointestinal/pembrolizumab-400mg-monotherapy-558.pdf"
    },
    {
        "id": 198,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab, PACLitaxel 175mg/m2, CARBOplatin AUC 5 and Bevacizumab Therapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/811-pembrolizumab-paclitaxel-carboplatin-auc.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-04-17",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/811-pembrolizumab-paclitaxel-carboplatin-auc.pdf"
    },
    {
        "id": 199,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/817-pembrolizumab-paclitaxel-carboplatin-auc-5-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-04-17",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/817-pembrolizumab-paclitaxel-carboplatin-auc-5-therapy.pdf"
    },
    {
        "id": 200,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Idelalisib and Ofatumumab Therapy, 2019, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/390.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2019-02-11",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/390.pdf"
    },
    {
        "id": 201,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Midostaurin Maintenance Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/661.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-12-08",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/661.pdf"
    },
    {
        "id": 202,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Midostaurin and Intermediate Dose Cytarabine Consolidation Therapy, 2023, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/683-midostaurin-intermediate-dose-cytarabine-consolidation-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-12-08",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/683-midostaurin-intermediate-dose-cytarabine-consolidation-therapy.pdf"
    },
    {
        "id": 203,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy - 21 day, 2024, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/281-gemcitabine-1250mg-m2-and-cisplatin-75mg-m2-therapy-21days.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-05-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/281-gemcitabine-1250mg-m2-and-cisplatin-75mg-m2-therapy-21days.pdf"
    },
    {
        "id": 204,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "CARBOplatin (AUC 6) and PACLitaxel 200mg/m2 Therapy, 2024, version number 7, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/304-carboplatin-auc6-and-paclitaxel-200mg-m2-therapy-.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-05-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/304-carboplatin-auc6-and-paclitaxel-200mg-m2-therapy-.pdf"
    },
    {
        "id": 205,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Gemcitabine (1000mg/m2) and CARBOplatin (AUC 5) Therapy - 21 day, 2024, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/310.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-05-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/310.pdf"
    },
    {
        "id": 206,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "PEMEtrexed and CISplatin Therapy, 2024, version number 6, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/317-pemetrexed-and-cisplatin-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-05-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/317-pemetrexed-and-cisplatin-therapy.pdf"
    },
    {
        "id": 207,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "PEMEtrexed and CARBOplatin Therapy, 2024, version number 5, NCCP National SACT Regimen, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/318-pemetrexed-and-carboplatin-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-05-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/318-pemetrexed-and-carboplatin-therapy.pdf"
    },
    {
        "id": 208,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Atezolizumab 840mg Monotherapy - 14 Day, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-02-19",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/592-atezolizumab-840mg-monotherapy.pdf"
    },
    {
        "id": 209,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Durvalumab Monotherapy 1500 mg - 28 day, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/655-durvalumab-1500mg-monotherapy-28-day.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-09-04",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/655-durvalumab-1500mg-monotherapy-28-day.pdf"
    },
    {
        "id": 210,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP) Therapy - 21 days, 2024, version number 5a, NCCP National SACT Regimen, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/307.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-09-04",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/307.pdf"
    },
    {
        "id": 211,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "RiTUXimab and Bendamustine Therapy, 2021, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/345.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-04-28",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/345.pdf"
    },
    {
        "id": 212,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "(R*)-DHAP Therapy, 2022, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/395-r-dhap-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-06-27",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/395-r-dhap-therapy.pdf"
    },
    {
        "id": 213,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Dose Adjusted riTUXimab, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine (DA-R EPOCH) Therapy, 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/355-dose-adjusted-r-epoch-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-06",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/355-dose-adjusted-r-epoch-therapy.pdf"
    },
    {
        "id": 214,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "(R*)-ICE ((riTUXimab), Ifosfamide, CARBOplatin and Etoposide) Therapy, 2022, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/397.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-09-21",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/397.pdf"
    },
    {
        "id": 215,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "(*riTUXimab) cycloPHOSphamide, DOXOrubicin, vinCRIStine and prednisoLONE (*R)-CHOP Therapy - 14 day, 2024, version number 5a, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/409.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-07-05",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/409.pdf"
    },
    {
        "id": 216,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "(R*)- miniCHOP Therapy - 21 days, 2023, version number 4, NCCP National SACT Regimen, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/436-r-minichop-therapy-%E2%80%93-21-days.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/436-r-minichop-therapy-%E2%80%93-21-days.pdf"
    },
    {
        "id": 217,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "R-Gemcitabine (1000mg/m2) Oxaliplatin Therapy - 14 day, 2020, version number 4, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/506.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-08-19",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/506.pdf"
    },
    {
        "id": 218,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "R-CEOP Therapy - 21 days, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/510-r-ceop-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-02-03",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/510-r-ceop-therapy.pdf"
    },
    {
        "id": 219,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Brentuximab vedotin and Bendamustine Therapy, 2019, version number 1, NCCP National SACT Regimen, NCCP, viewed 04/04/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/529-brentuximab-vedotin-and-bendamustine-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2019-10-18",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/529-brentuximab-vedotin-and-bendamustine-therapy.pdf"
    },
    {
        "id": 220,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "riTUXimab 375 mg/m2 Combination Therapy-21 day, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-03-31",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/542-rituximab-375-mg-m2-combination-therapy-21-day.pdf"
    },
    {
        "id": 221,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "RiTUXimab 375 mg/m2 Maintenance Therapy- 56 day, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/543-rituximab-375-mg-m2-maintenance-therapy-56-day.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-03-31",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/543-rituximab-375-mg-m2-maintenance-therapy-56-day.pdf"
    },
    {
        "id": 222,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "riTUXimab (S/C 1400mg) Maintenance Therapy-84 day, 2022, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/599.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-10-12",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/599.pdf"
    },
    {
        "id": 223,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "riTUXimab (S/C 1400mg) Maintenance Therapy-56 day, 2022, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/600.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-10-12",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/600.pdf"
    },
    {
        "id": 224,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Dose Adjusted riTUXimab S/C, Etoposide, prednisoLONE, DOXOrubicin, cycloPHOSphamide and vinCRIStine, 2023, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/dose-adjusted-rituximab-s-c-etoposide-prednisolone-doxorubicin-cyclophosphamide-and-vincristine-da-r-s-c-epoch-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-11-06",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/dose-adjusted-rituximab-s-c-etoposide-prednisolone-doxorubicin-cyclophosphamide-and-vincristine-da-r-s-c-epoch-therapy.pdf"
    },
    {
        "id": 225,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "riTUXimab, Cyclophosphamide, vinCRIStine and prednisoLONE R-CVP Therapy-21 days, 2022, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/r-cvp-v3-293.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2022-06-27",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/r-cvp-v3-293.pdf"
    },
    {
        "id": 226,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "RiTUXimab 375 mg/m2 Maintenance Therapy-84 day, 2021, version number 2, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/rituximab-375-mg-m2-maintenance-therapy-84-day.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2021-03-31",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lymphoma-myeloma/rituximab-375-mg-m2-maintenance-therapy-84-day.pdf"
    },
    {
        "id": 227,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Imatinib Therapy - GIST, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/335-imatinib-therapy-gist.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-07-21",
        "organization": "National Cancer Control Programme",
        "publication_date": "2020-07-15",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/sarcoma/335-imatinib-therapy-gist.pdf"
    },
    {
        "id": 228,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Tepotinib Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 19/08/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/823-tepotinib-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-08-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-08-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/823-tepotinib-therapy.pdf"
    },
    {
        "id": 229,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Trastuzumab Deruxtecan (Enhertu) Therapy, 2024, version number 1, NCCP National SACT Regimen, NCCP, viewed 19/08/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/776-trastuzumab-deruxtecan-enhertu-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-08-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-08-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/776-trastuzumab-deruxtecan-enhertu-therapy.pdf"
    },
    {
        "id": 230,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab 400mg, CARBOplatin AUC 5 and weekly PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 19/08/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/860-pembrolizumab-400mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-and-cyclophosphamide-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-08-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-06-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/860-pembrolizumab-400mg-carboplatin-auc-5-and-weekly-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-and-cyclophosphamide-therapy.pdf"
    },
    {
        "id": 231,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Pembrolizumab 400mg, Weekly CARBOplatin AUC 1.5 and PACLitaxel 80mg/m2 followed by Dose Dense DOXOrubicin and cycloPHOSphamide (AC 60/600) Therapy, 2024, version number 1a, NCCP National SACT Regimen, NCCP, viewed 19/08/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/861-pembrolizumab-400mg-weekly-carboplatin-auc-1-5-and-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-and-cyclophosphamide-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-08-19",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-07-18",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/861-pembrolizumab-400mg-weekly-carboplatin-auc-1-5-and-paclitaxel-80mg-m2-followed-by-dose-dense-doxorubicin-and-cyclophosphamide-therapy.pdf"
    },
    {
        "id": 232,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Vandetanib Therapy, 2023, version number 5, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/242vandetanibmonotherapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-09-01",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-02-07",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/headandneck/242vandetanibmonotherapy.pdf"
    },
    {
        "id": 233,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Trentinoin (ATRA) and Arsenic Trioxide (ATO) Induction Therapy, 2023, version number 4, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/356-tretinoin-atra-with-arsenic-trioxide-ato-induction-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-09-01",
        "organization": "National Cancer Control Programme",
        "publication_date": "2023-09-20",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/leukemia-bmt/356-tretinoin-atra-with-arsenic-trioxide-ato-induction-therapy.pdf"
    },
    {
        "id": 234,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Sacituzumab Govitecan Therapy, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 01/09/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/794-sacituzumab-govitecan-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-09-01",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-08-29",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/794-sacituzumab-govitecan-therapy.pdf"
    },
    {
        "id": 235,
        "label": "",
        "description": "",
        "alternativeLabels": "",
        "citation": "Entrectinib Monotherapy - Adult, 2024, version number 2, NCCP National SACT Regimen, NCCP, viewed 16/10/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf",
        "document_type": "Government agency",
        "last_updated": "2024-10-16",
        "organization": "National Cancer Control Programme",
        "publication_date": "2024-10-01",
        "url": "https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/lung/702-entrectinib-therapy.pdf"
    }
]